Alderley Lighthouse Labs is a UKAS-accredited medical laboratory specialising in human diagnostics, providing clinically led pathology and laboratory testing services to private clinics, hospitals, GPs, the NHS, pharmaceutical and occupational health companies. Its comprehensive testing capabilities focus on delivering accurate and timely diagnostic results to improve healthcare outcomes.
Founder in 2022, the business was established by Mark Wigglesworth and Simon Chapman, who previously played leading roles in developing and operating the government’s COVID-19 testing facility at Alderley Park. Since launching, Alderley Lighthouse Labs has expanded its customer base, grown its revenues and continued to broaden its service offering across a range of specialist and advanced diagnostic areas.
The business offers an extensive range of advanced and specialised testing services, including genetic and molecular testing, infectious disease panels, oncology and haematology profiles, pharmacogenomics, women’s health testing, cardiac biomarkers and hormonal, nutritional and metabolic assessments.
“We are delighted to reaffirm our commitment to Alderley following the delivery of key commercial milestones. Since our initial investment through the Northern Powerhouse Investment Fund the business has significantly grown its revenues through new customer acquisition and increased volumes with existing clients. This new investment from the Maven VCTs will enable Alderley to continue its impressive growth trajectory and expand its footprint in the attractive healthcare diagnostic services market.”
Gavin Bell, Investment Director at Maven
Meet the lead executive(s)
Subscribe for email updates
